S11 Ep8: Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC
OncLive® On Air - Podcast tekijän mukaan OncLive® On Air
Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.
